These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23073173)

  • 1. Bicalutamide-induced hypoxia potentiates RUNX2-mediated Bcl-2 expression resulting in apoptosis resistance.
    Browne G; Nesbitt H; Ming L; Stein GS; Lian JB; McKeown SR; Worthington J
    Br J Cancer; 2012 Nov; 107(10):1714-21. PubMed ID: 23073173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitric Oxide Up-Regulates RUNX2 in LNCaP Prostate Tumours: Implications for Tumour Growth In Vitro and In Vivo.
    Nesbitt H; Browne G; O'Donovan KM; Byrne NM; Worthington J; McKeown SR; McKenna DJ
    J Cell Physiol; 2016 Feb; 231(2):473-82. PubMed ID: 26189652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression.
    Nesbitt H; Byrne NM; Williams SN; Ming L; Worthington J; Errington RJ; Patterson LH; Smith PJ; McKeown SR; McKenna DJ
    Clin Cancer Res; 2017 Apr; 23(7):1797-1808. PubMed ID: 27697998
    [No Abstract]   [Full Text] [Related]  

  • 4. Androgen deprivation results in time-dependent hypoxia in LNCaP prostate tumours: informed scheduling of the bioreductive drug AQ4N improves treatment response.
    Ming L; Byrne NM; Camac SN; Mitchell CA; Ward C; Waugh DJ; McKeown SR; Worthington J
    Int J Cancer; 2013 Mar; 132(6):1323-32. PubMed ID: 22915157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms.
    De Petrocellis L; Ligresti A; Schiano Moriello A; Iappelli M; Verde R; Stott CG; Cristino L; Orlando P; Di Marzo V
    Br J Pharmacol; 2013 Jan; 168(1):79-102. PubMed ID: 22594963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
    Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased resistance to trail-induced apoptosis in prostate cancer cells selected in the presence of bicalutamide.
    Mitterberger M; Neuwirt H; Cavarretta IT; Hobisch A; Culig Z
    Prostate; 2007 Aug; 67(11):1194-201. PubMed ID: 17520660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen deprivation in LNCaP prostate tumour xenografts induces vascular changes and hypoxic stress, resulting in promotion of epithelial-to-mesenchymal transition.
    Byrne NM; Nesbitt H; Ming L; McKeown SR; Worthington J; McKenna DJ
    Br J Cancer; 2016 Mar; 114(6):659-68. PubMed ID: 26954717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells.
    Ogura T; Tanaka Y; Tamaki H; Harada M
    Int J Oncol; 2016 Jun; 48(6):2330-8. PubMed ID: 27082738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does androgen-ablation therapy (AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells?
    Bennett HL; Stockley J; Fleming JT; Mandal R; O'Prey J; Ryan KM; Robson CN; Leung HY
    BJU Int; 2013 Apr; 111(4):672-82. PubMed ID: 22897391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2.
    Feng S; Tang Q; Sun M; Chun JY; Evans CP; Gao AC
    Mol Cancer Ther; 2009 Mar; 8(3):665-71. PubMed ID: 19240160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia.
    Nomura T; Yamasaki M; Hirai K; Inoue T; Sato R; Matsuura K; Moriyama M; Sato F; Mimata H
    Mol Cancer; 2013 Apr; 12():27. PubMed ID: 23566222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L; Giocanti N; Hennequin C; Favaudon V
    Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment.
    Müller SA; Holzapfel K; Seidl C; Treiber U; Krause BJ; Senekowitsch-Schmidtke R
    Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1434-42. PubMed ID: 19352653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.
    McGregor N; Patel L; Craig M; Weidner S; Wang S; Pienta KJ
    J Cell Biochem; 2010 Aug; 110(5):1187-94. PubMed ID: 20589722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bicalutamide enhances fodrin-mediated apoptosis through calpain in LNCaP.
    Lee J; Mun S; Park A; Kim D; Heun Cha B; Kang HG
    Exp Biol Med (Maywood); 2018 Jun; 243(10):843-851. PubMed ID: 29860890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
    Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
    Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide.
    Madarová J; Lukesová M; Hlobilková A; Riháková P; Murray PG; Student V; Vojtsek B; Kolár Z
    Neoplasma; 2001; 48(5):419-24. PubMed ID: 11845989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short hairpin RNA library-based functional screening identified ribosomal protein L31 that modulates prostate cancer cell growth via p53 pathway.
    Maruyama Y; Miyazaki T; Ikeda K; Okumura T; Sato W; Horie-Inoue K; Okamoto K; Takeda S; Inoue S
    PLoS One; 2014; 9(10):e108743. PubMed ID: 25285958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.